Kymera Therapeutics Announces Sanofi's Expansion of Two Phase 2 Trials for IRAK4 PROTAC KT-474, Driving 10% Post-Market Stock Surge

▎Armstrong

On July 8, 2024, Kymera Therapeutics announced that, following the IDRC's review of the data, its partner Sanofi decided to expand two Phase II clinical trials for KT-474 in treating hidradenitis suppurativa and atopic dermatitis, aiming to accelerate progress toward pivotal clinical trials.

Kymera Therapeutics' stock price rose 10% in after-hours trading yesterday, reaching a market value of $2.2 billion.

KT-474 is a KRAK4 PROTAC molecule, part of Kymera's core pipeline, and has reached a collaborative development agreement with Sanofi. The subsequent pipeline includes STAT6 PROTAC, TYK2 PROTAC, STAT3 PROTAC, MDM2 PROTAC, and more.

Kymera still has $745 million in cash, which can sustain operations until the first half of 2027.

KT-474 Two Phase II Clinical Trials Originally Planned to Enroll 99 and 115 Patients; Sanofi Decides to Expand Scale and Accelerate Progress to Pivotal Clinical Trials

Summary

In China, the IRAK4 PROTAC developed by LeadBio has entered Phase I clinical trials, and the IRAK4 PROTAC from BeiGene received IND approval at the end of May this year. In recent years, autoimmune drugs have been particularly popular in the U.S. stock market, and the IRAK4 PROTAC is another strong potential competitor in the autoimmune field.